Erik William Nielsen, MD | |
3885 Se Augusta Pl, Gresham, OR 97080-8422 | |
(503) 793-5230 | |
(503) 665-4756 |
Full Name | Erik William Nielsen |
---|---|
Gender | Male |
Speciality | Anesthesiology |
Location | 3885 Se Augusta Pl, Gresham, Oregon |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1588747448 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | MD12909 (Oregon) | Primary |
207L00000X | Anesthesiology | G41366 (California) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Erik William Nielsen, MD 3885 Se Augusta Pl, Gresham, OR 97080-8422 Ph: (503) 793-5230 | Erik William Nielsen, MD 3885 Se Augusta Pl, Gresham, OR 97080-8422 Ph: (503) 793-5230 |
News Archive
The National Comprehensive Cancer Network, a Centers for Medicare & Medicaid Services-approved provider-led entity for imaging appropriate use criteria, continues to build its library of AUC and has published NCCN Imaging Appropriate Use Criteria for eight new cancer types. Launched in June 2016, NCCN Imaging AUC currently are available for 20 cancer types.
Gene mutations responsible for causing cataracts in children have been identified by a team of University of Utah vision researchers. The discovery was reported in a recent issue of The Journal of Medical Genetics.
Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer, according to a large study presented by Christopher Sweeney, MBBS of Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology, during the American Society of Clinical Oncology Annual Meeting.
A protein frequently found in high levels in breast cancer cells helps tumours to survive and grow, and could be targeted with a new type of drug that is already being tested for other cancers, new research reveals.
The last patient in the EU Diamyd Phase III clinical study has completed the 15-month visit, meaning that all patients in this study have completed the main 15 month study period in this trial. This important achievement in the Diamyd® Phase III program will now be followed by an intense period where the data will be compiled from the more than 60 clinics throughout Europe and from the central laboratory.
› Verified 6 days ago
Dr. Timothy O. Noreuil, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 3868 Se Deer Creek Way, Gresham, OR 97080 Phone: 503-413-7711 | |
Bahar M Ahady, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 2840 Se Cleveland Dr, Gresham, OR 97080 Phone: 971-222-8770 | |
Adrian Anthony, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 689 Nw Burnside Rd, Gresham, OR 97030 Phone: 503-382-8100 |